DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
FI: 5,818
Type: Article
Collaboration
Year: 2022
Writers
Hidalgo-Tenorio, C; Pasquau, J; Vinuesa, D; Ferra, S; Terron, A; SanJoaquin, I; Payeras, A; Martinez, O.J. Lopez-Ruz, MA; Omar, M; de la Torre-Lima, J; Lopez-Lirola, A; Palomares, J; White, JR; Montero, M; Garcia-Vallecillos, C
Magazine
Title: VIRUSES-BASEL
Quartile
- Q2